Jeanmarie Guenot is the perfect combination of business expertise and scientific excellence, having done Masters in Business Administration from the University of Pennsylvania’s The Wharton School of Business and her Ph.D. from the University of California. She currently leads one of the most prominent biotech firms in the field of cancer therapies and hematologic malignancies, Amphivena Therapuetics Inc, where Jeanmarie serves as the CEO and the President of the company.
Jeanmarie started her career as the team leader and principal scientists at Hoffman-La Roche, where she worked for six years, after which she moved to joining Atlas Ventures. Jeanmarie worked at Atlas Ventures for another three years, between 2000 to 2003, before moving to PDL BioPharma, where she was named the Vice President of Corporate and Business Development. According to amphivena.com, Jeanmarie worked at PDL BioPharma for the next five years, and helped the firm with mergers and acquisitions, alliance management, client management, scientific collaborations and research and development, before starting her business consultancy firm named Guenot, LLC in 2008.
In 2009, Jeanmarie Guenot also founded SKS Ocular, LLC, which researched on drug delivery techniques and finding effective therapies for glaucoma, ocular inflammation, and macular degeneration. Amphivena Therapeutics Inc, where Jeanmarie is currently working, is a firm headquartered in San Francisco, California. As one of the leading biopharmaceutical companies in the country, it aims to research and find more efficient oncology therapies and help patients suffering from terminal diseases, including blood cancer. Amphivena Therapeutics Inc at https://www.takeda.com/news/2017/20170111_7659.html aims to help the patients through the treatments that would improve the strength of the immune system to fight cancer cells and tumors.
Under the visionary leadership of Jeanmarie Guenot, Amphivena Therapeutics Inc was able to sign a trade agreement with Janssen Biotech Inc, which helped Amphivena Therapeutics get the funds required to further their research. Jeanmarie, for her excellent performance and streams of achievements throughout her career, has been featured in numerous media publications and networks, including Business Wire and Marketwired.
Guenot continues to play an active role in helping Amphivena Therapeutics Inc, become a global name in the field of cancer therapies and finding a cure for hematologic malignancies.